Posters & Publications

HER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner

Presented at: 2019 Society for Immunotherapy of Cancer (SITC)

TLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity

Presented at: 2019 American Association for Cancer Research (AACR)

Systemic immunity is required for effective cancer immunotherapy

Spitzer MH et al., Cell (2017)

Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity

Carmi Y, et al., Nature (2015)